Drug Trial Radar · NCT07852195
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
432
Planned (sponsor's estimate)
Start
Jan 6, 2027
Primary completion
Mar 31, 2029
Study completion Mar 31, 2030
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and keeps growing even when the amount of testosterone in the body is reduced to very low levels (castration-resistant). Usual care treatment for patients with metastatic prostate cancer includes surgery or medical castration which involves drugs to suppress the function of the testes. After receiving this therapy, a period of disease stability occurs, followed typically by cancer regrowth and castration-resistant disease. Castration-resistant prostate cancer occurs because the tumor cells are eventually able to adapt to the very low levels of testosterone in the body. A new type of therapy called Bipolar Androgen Therapy (BAT) involves giving patients very high doses of testosterone every 28 days. This results in a cycle of higher than normal testosterone levels (i.e., "supraphysiologic") to near castrate levels over the 28 days. BAT may be able to stop prostate tumor cells from becoming castrate-resistant. In this trial, patients who receive BAT with high dose testosterone and experience disease progression then receive darolutamide. Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Adding BAT with high dose testosterone prior to darolutamide after disease progression may help shrink or stabilize metastatic castration-resistant prostate cancer better than usual treatments alone.
Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone AcetateDrug
Given PO
Biospecimen CollectionProcedure
Undergo biospecimen collection
Bone ScanProcedure
Undergo bone imaging
CabazitaxelDrug
Given IV
Computed TomographyProcedure
Undergo CT
DarolutamideDrug
Given PO
DexamethasoneDrug
Given dexamethasone
DocetaxelDrug
Given IV
EnzalutamideDrug
Given PO
Lutetium Lu 177 Vipivotide TetraxetanDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
MethylprednisoloneDrug
Given methylprednisolone
PrednisoneDrug
Given prednisone
Questionnaire AdministrationOther
Ancillary studies
Testosterone CypionateDrug
Given IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Second progression-free survival (PFS2) (Phase II)Time frame: From randomization to disease progression or death, whichever occurs first after initiation of second treatment (standard of care [SOC]2 or darolutamide), assessed up to 60 months
- Overall survival (OS) (Phase III)Time frame: From randomization until death from any cause or date last known alive, assessed up to 60 months
- Overall quality of life (QOL)Time frame: At randomization,12, 24 and 48 weeks after randomization
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.